Steve Schonfeld’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.21M | Buy |
+57,030
| New | +$7.51M | 0.03% | 517 |
|
|
2025
Q4 | – | Sell |
-248,895
| Closed | -$27.6M | – | 2236 |
|
|
2025
Q3 | $27.6M | Sell |
248,895
-173,658
| -41% | -$19.7M | 0.16% | 121 |
|
|
2025
Q2 | $46.8M | Buy |
422,553
+348,432
| +470% | +$37.1M | 0.32% | 50 |
|
|
2025
Q1 | $8.31M | Sell |
74,121
-437,211
| -86% | -$45.1M | 0.05% | 379 |
|
|
2024
Q4 | $47.2M | Sell |
511,332
-79,159
| -13% | -$7.13M | 0.27% | 45 |
|
|
2024
Q3 | $49.5M | Sell |
590,491
-187,449
| -24% | -$14.3M | 0.33% | 31 |
|
|
2024
Q2 | $53.4M | Buy |
777,940
+519,925
| +202% | +$34.7M | 0.34% | 37 |
|
|
2024
Q1 | $18.9M | Sell |
258,015
-128,102
| -33% | -$9.85M | 0.13% | 183 |
|
|
2023
Q4 | $31.3M | Buy |
386,117
+374,156
| +3,128% | +$29.1M | 0.21% | 80 |
|
|
2023
Q3 | $896K | Buy |
+11,961
| New | +$920K | 0.01% | 1050 |
|
|
2023
Q2 | – | Sell |
-32,257
| Closed | -$2.68M | – | 2269 |
|
|
2023
Q1 | $2.68M | Sell |
32,257
-42,807
| -57% | -$3.55M | 0.03% | 611 |
|
|
2022
Q4 | $6.44M | Sell |
75,064
-45,828
| -38% | -$3.63M | 0.05% | 410 |
|
|
2022
Q3 | $7.46M | Sell |
120,892
-54,584
| -31% | -$3.44M | 0.06% | 400 |
|
|
2022
Q2 | $10.8M | Buy |
175,476
+52,576
| +43% | +$3.26M | 0.11% | 252 |
|
|
2022
Q1 | $7.31M | Buy |
122,900
+28,989
| +31% | +$1.85M | 0.07% | 335 |
|
|
2021
Q4 | $6.82M | Buy |
+93,911
| New | +$6.47M | 0.06% | 384 |
|
|
2021
Q2 | – | Sell |
-91,637
| Closed | -$5.92M | – | 2070 |
|
|
2021
Q1 | $5.92M | Buy |
91,637
+60,937
| +198% | +$3.93M | 0.07% | 370 |
|
|
2020
Q4 | $1.79M | Buy |
30,700
+17,827
| +138% | +$1.08M | 0.02% | 624 |
|
|
2020
Q3 | $814K | Sell |
12,873
-20,324
| -61% | -$1.41M | 0.02% | 758 |
|
|
2020
Q2 | $2.55M | Buy |
33,197
+6,379
| +24% | +$489K | 0.07% | 346 |
|
|
2020
Q1 | $2M | Sell |
26,818
-147,530
| -85% | -$10.2M | 0.13% | 197 |
|
|
2019
Q4 | $11.3M | Buy |
174,348
+151,848
| +675% | +$9.89M | 0.28% | 97 |
|
|
2019
Q3 | $1.43M | Sell |
22,500
-29,874
| -57% | -$1.95M | 0.04% | 389 |
|
|
2019
Q2 | $3.54M | Sell |
52,374
-57,235
| -52% | -$3.77M | 0.13% | 199 |
|
|
2019
Q1 | $7.13M | Buy |
109,609
+66,703
| +155% | +$4.43M | 0.25% | 108 |
|
|
2018
Q4 | $2.68M | Buy |
42,906
+33,406
| +352% | +$2.33M | 0.1% | 264 |
|
|
2018
Q3 | $733K | Sell |
9,500
-600
| -6% | -$45.3K | 0.03% | 496 |
|
|
2018
Q2 | $716K | Buy |
10,100
+3,741
| +59% | +$264K | 0.04% | 462 |
|
|
2018
Q1 | $480K | Buy |
+6,359
| New | +$505K | 0.04% | 487 |
|
|
2017
Q3 | – | Sell |
-98,171
| Closed | -$6.95M | – | 665 |
|
|
2017
Q2 | $6.95M | Buy |
+98,171
| New | +$6.53M | 0.72% | 21 |
|
|
2017
Q1 | – | Sell |
-9,828
| Closed | -$704K | – | 647 |
|
|
2016
Q4 | $704K | Sell |
9,828
-9,047
| -48% | -$672K | 0.09% | 278 |
|
|
2016
Q3 | $1.49M | Buy |
18,875
+4,730
| +33% | +$384K | 0.25% | 109 |
|
|
2016
Q2 | $1.18M | Buy |
14,145
+8,137
| +135% | +$722K | 0.26% | 110 |
|
|
2016
Q1 | $552K | Buy |
+6,008
| New | +$542K | 0.23% | 123 |
|
Other funds holding GILD
Steve Schonfeld's GILD Position: Q2 2026 in Review
Steve Schonfeld opened a new position in Gilead Sciences (GILD) in Q2 2026: 57,030 shares worth $7.21M. The stake represents 0.03% of the portfolio and ranks #517 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in GILD as recently as Q3 2025.
Steve Schonfeld first reported a position in GILD in Q1 2016 and has held it in 34 quarters since. The position peaked at $53.4M in Q2 2024. 2,265 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Steve Schonfeld held 57,030 shares of Gilead Sciences worth $7.21M as of Q2 2026.
- Gilead Sciences was a new Steve Schonfeld position in Q2 2026.
- Gilead Sciences made up 0.03% of Steve Schonfeld's portfolio in Q2 2026, its #517 holding.
- Steve Schonfeld first reported a position in Gilead Sciences in Q1 2016 and has held it in 34 quarters since.
- Steve Schonfeld's Gilead Sciences position peaked at $53.4M in Q2 2024.
- 2,265 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.